TPG-backed drugmaker Aptalis files for IPO of up to $500 million
(Reuters) - Specialty drugmaker Aptalis Holdings Inc, owned by private equity firm TPG Capital LP, filed with U.S. regulators to raise up to $500 million in an initial public offering of its common stock.
Goldman Sachs, J.P. Morgan, Barclays and Evercore are underwriting the IPO, the company told the U.S. Securities and Exchange Commission in a preliminary prospectus.
In October, Reuters had reported that the drugmaker appointed underwriters for an IPO after efforts to sell the company failed.
The filing did not reveal how many shares Aptalis planned to sell or their expected price.
The Bridgewater, New Jersey-based company intends to list its common stock on the Nasdaq under the symbol "APTA."
The amount of money a company says it plans to raise in its first IPO filings is used to calculate registration fees. The final size of the IPO could be different.
(Reporting by Avik Das in Bangalore; Editing by Joyjeet Das)
TOKYO - Asian shares cautiously rebounded from two-week lows on Thursday though investors were in no mood to embrace risk ahead of a batch of Chinese data that may offer clues about the extent of its economic slowdown.
HELSINKI - Finnish start-up Next Games has raised $6 million in funding in the latest of several venture capital investments in the Nordic country's booming mobile games industry, the company said on Wednesday.
BEIJING/HONG KONG - China reiterated its opposition on Thursday to a European Union plan to limit airline carbon dioxide emissions and called for talks to resolve the issue a day after its major airlines refused to pay any carbon costs under the new law.